Results 71 to 80 of about 296,469 (371)
This study explores nanoparticle delivery of the protein kinase C inhibitor bisindolylmaleimide‐I (BIM‐I) to combat influenza A virus infections. Encapsulation in biodegradable PLGA nanoparticles improved safety while maintaining the compound's strong antiviral activity.
Laura Klement +12 more
wiley +1 more source
Rasha Youssef Hagag,1,* Ahmed Fawzy Selim,1,* Omneya Mohamed Darrag,1 Hassan Zied,2 Mohamed Sabry Aboelnasr1 1Department of internal medicine, Faculty of medicine, Tanta University, Tanta, Egypt; 2Kafr-Elsheikh Liver Institute, Kafr-Elsheikh, Egypt*These
Hagag RY +4 more
doaj
Background/AimsTo evaluate the era of direct acting antivirals (DAAs), we must understand the treatment patterns and outcomes of interferon-based therapy for hepatitis C virus (HCV) infection.
Eun Sun Jang +7 more
doaj +1 more source
A fixed-dose combination of sofosbuvir/velpatasvir (SOF/VEL) plus weight-based ribavirin (RBV) for 12 weeks is recommended for the treatment of patients with hepatitis C virus (HCV)-associated decompensated cirrhosis. However, large global studies, while
Steven Flamm +14 more
doaj +1 more source
Clinical-evolutional particularities of the cryoglobulinemic vasculitis in the case of a patient diagnosed with hepatitis C virus in the predialitic phase [PDF]
Hepatitis C virus (HCV) represents a fundamental issue for public health, with long term evolution and the gradual appearance of several complications and associated pathologies.
Boldeanu, Lidia +12 more
core +3 more sources
This study finds that CD8⁺ TSCM cells exhibit superior self‐renewal, differentiation, and antiviral activity. Transcriptome and epigenome analyses highlight MAPK cascade regulation in TSCM cells. In vivo, virus‐specific TSCM cells show enhanced persistence and tumor protection.
Xun‐Hong Cao +13 more
wiley +1 more source
Single nucleotide polymorphisms of interleukin-28B (IL28B) rs8099917 are reported to be associated with virologic clearance in interferon-and ribavirin -based treatment for hepatitis C virus (HCV)-infected patients.
Nobuhiro Harada +11 more
doaj +1 more source
Role of IL-28B and inosine triphosphatase polymorphisms in efficacy and safety of Peg-Interferon and ribavirin in chronic hepatitis C compensated cirrhosis with and without oesophageal varices. [PDF]
Genetic factors can influence the outcome of antiviral therapy in chronic hepatitis C (HCV). We evaluated the role of interleukin-28B single nucleotide polymorphisms (SNPs) and inosine triphosphatase (ITPA) gene variants in HCV cirrhosis treated with Peg-
Aghemo +27 more
core +1 more source
Hepatitis C virus-associated hepatocellular carcinoma after sustained virologic response
The introduction of a direct-acting antiviral (DAA) for patients with hepatitis C virus (HCV) infection, could lead to higher sustained virologic response (SVR) rates with fewer adverse events, and it could shorten the treatment duration relative to the interferon era. Although most recent clinical studies have demonstrated that the occurrence rates of
Sasaki, Reina +4 more
openaire +2 more sources
Amid the ongoing threat of emerging viral pathogens, host‐directed antivirals offer a strategy to overcome viral mutation and drug resistance. SB2960, a small‐molecule inducer of stress granules (SGs), exhibits potent broad‐spectrum antiviral activity with minimal cytotoxicity.
Wan Gi Byun +14 more
wiley +1 more source

